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Abstract 
Systematic epistasis analyses in multifactorial disorders are an important step to better characterize 
complex genetic risk structures. We conducted a hypothesis-free sex-stratiﬁed genome-wide 
screening for epistasis contributing to Alzheimer’s disease (AD) susceptibility. We identiﬁed a 
statistical epistasis signal between the single nucleotide polymorphisms rs3733980 and rs7175766 
that was associated with AD in males (genome-wide signiﬁcant pBonferroni-corrected¼0.0165). This 
signal pointed toward the genes WW and C2 domain containing 1, aka KIBRA; 5q34 and TLN2 (talin 
2; 15q22.2). Gene-based meta-analysis in 3 independent consortium data sets conﬁrmed the 
identiﬁed interaction: the most signiﬁcant (pmeta-Bonferroni-corrected¼9.02*10฀3) was for the 
single nucleotide polymorphism pair rs1477307 and rs4077746. In functional studies, WW and C2 
domain containing 1, aka KIBRA and TLN2 coexpressed in the temporal cortex brain tissue of AD 
subjects (b¼0.17, 95% CI 0.04 to 0.30, p¼0.01); modulated Tau toxicity in Drosophila eye 
experiments; colocalized in brain tissue cells, N2a neuroblastoma, and HeLa cell lines; and 
coimmunoprecipitated both in brain tissue and HEK293 cells. Our ﬁnding points toward new AD-
related pathways and provides clues toward novel medical targets for the cure of AD. 
1. Introduction 
Alzheimer’s disease (AD) is a progressive, irreversible neurode-generative disorder characterized by 
the development of amyloid plaques and neuroﬁbrillary tangles, the loss of connections between 
neurons, and nerve cell death. AD is highly heritable and genetically heterogeneous with 58%e79% 
of risk attributed to genetic factors (Gatz et al., 2006; Sims and Williams, 2016). Although genome-
wide association studies have strongly improved our knowledge of AD genetics (Ridge et al., 2013), 
genetic risk factors explain no more than 30% of heritability (Cuyvers and Sleegers, 2016). In this 
contribution, we focus on late-onset AD, the most common form of the disease with onset age >65 
years. The most established genetic factor for AD, apolipoprotein E gene ([APOE] gene, 19q13), 
exhibits allelic hetero-geneitydAPOE’s ε4 allele is a risk enhancer, whereas the ε2 allele is protective 
(Bertram et al., 2007). 
AD presents notable sexual dimorphism (Mielke et al., 2014). Records exist of sex differences in the 
brain, such as in brain anat-omy, age-related declines in brain volume and brain glucose metabolism 
(Carter et al., 2012), and sex hormones inﬂuencing AD progression (Musicco, 2009). Risk associated 
with the APOE-e4 allele is stronger in females than in males, and loss of chromosome Y have been 
associated with increased AD risk in males (Dumanski et al., 2016). These data support complex 
interplay between sex and genetic background regarding AD predisposition. 
Gene regulatory and biochemical networks create dependencies among genes that are realized as 
gene-gene interactions (epistasis) (Templeton, 2000). Although epistasis has been well studied in 
model organisms using biological experiments (Miko, 2008), hypothesis-free discovery of biological 
epistasis via statistical methods remains challenging in humans. This is in part due to the conceptual 
discrepancy between statistical and biological epistasis (Moore, 2005), the utility of oversimpliﬁed 
population-level models to capture complex individual phenomena, insufﬁcient power, and the gross 
multiple testing burden inherent in genome-wide epistasis screening. Therefore, most evidence for 
epistasis in AD is hypothesis-driven, using prior biological or statistical knowledge (Ebbert et al., 
2015). The same holds for sex-speciﬁc searches for coinvolvement of multiple genetic loci in AD 
(Medway et al., 2014). 
Gusareva et al. published the ﬁrst replicable interaction associated with AD using a genome-wide 
exhaustive screening approach that combines strengths over different analytic approaches 
(Gusareva and Van Steen, 2014), identiﬁed a statistical interaction between KHDRBS2 (rs6455128) 
and CRYL1 (rs7989332), and exhibited down-stream functional consequences (Gusareva et al., 2014). 
Here, we used the same European AD Initiative Investigators (EADI1) consortium cohort (Lambert et 
al., 2009) (2259/6017 AD cases/controls) and an adapted hypothesis-free genome-wide exhaustive 
epistasis screening protocol to identify sex-speciﬁc interactions with AD. We identiﬁed AD-
associated male-speciﬁc statistical interaction between variants of the genes WWC1 (WW and C2 
domain containing 1 or kidney and brain expressed protein, aka KIBRA; locus 15q22.2) and TLN2 
(talin 2, locus 15q22.2). This novel statistical epistasis signal was replicated in 2 of 3 independent 
consortium data sets via gene-based replication strategy (Gusareva and Van Steen, 2014). Extensive 
biological validation studies (subcellular colocalization and immunoprecipitation [IP] analyses, 
transcriptome analysis, experiments in model organisms [Drosophila melanogaster], as well as in 
silico protein docking and molecular dynamics assessments) further helped elucidate the epistatic 
relationship. 
2. Methods 
2.1. Study populations 
The discovery cohort consisted of a sample of 2259 late-onset AD patients and 6017 controls from 3 
cities in France (Bordeaux, Dijon, and Montpellier), as part of EADI1. Follow-up statistical analyses 
used data from 3 AD consortia: (1) the Genetic and Environmental Risk for AD consortium (GERAD1) 
including cohorts from Germany, UK, and the USA (Harold et al., 2009); (2) the Rotterdam Study (RS), 
a prospective cohort study that started in 1990 in Rotterdam (the Netherlands) (Hofman et al., 
2013); and (3) the AD Genetic Consortium (ADGC) that collects genetic data from over 30 studies in 
the US (Naj et al., 2011). Data collection quality control procedures have been described in the 
corresponding references. Only subjects with complete information on sex and age were included in 
the analyses. Sex-speciﬁc sample size distributions and age characteristics are given in the Table S1. 
2.2. Genotyping 
The EADI1 and RS samples were genotyped by Illumina Human 610-Quad BeadChip (Hofman et al., 
2013; Lambert et al., 2009), the GERAD1 samples by Illumina 610-quad chip and by Illumina 
HumanHap550 Beadchip (Harold et al., 2009), the ADGC subjects by Illumina or Affymetrix high-
density single nucleotide poly-morphism (SNP) microarrays (Naj et al., 2011). Applied genotype 
ﬁltering procedure as described in the Note S2 leaving 312,064 SNPs for epistasis analyses with 
EADI1. Replication cohorts used only directly genotyped SNPs. 
2.3. Statistical discovery and replication analysis 
Following guidelines in Gusareva et al. (Gusareva and Van Steen, 2014), we tested for all pairwise 
statistical interactions between SNPs in association to AD in sex-stratiﬁed samples within EADI1. Two 
different analytic techniques both parametric (customized version of the BOolean Operation-based 
Screening and Testing [BOOST] (Wan et al., 2010) with stringent Bonferroni correction) and 
nonparametric (model-based multifactor dimensionality reduction [MB-MDR]) (Cattaert et al., 2011; 
Van Lishout et al., 2013) that uses permutation-based gammaMAXT algorithm for multiple testing 
correction (Lishout et al., 2015) were adopted in this study with default options (Note S3). Statistical 
epistasis signals at the genome-wide signiﬁcance level of 0.05 were followed up with a logistic 
regression analyses adjusting for age at time of subject examination and the ﬁrst 4 SNP-based 
principal components (to adjust for confounding by shared genetic ancestry). Evidence of interaction 
was based on a likelihood-ratio test statistic with 4 degrees of freedom to reﬂect 2 SNPs with 3 
genotypes each (in the absence of missing multilocus genotypes). Main effect single-SNP 
associations were assessed via Cochrane-Armitage trend test in SVS Version 7.5 software (Golden 
Helix, Inc). 
For replication analysis, we selected 68 and 98 SNPs assigned to WWC1 (5q34: 167651670-
167829334 bp) and TLN2 (15q22.2: 60726802-60920733 bp), respectively, according to NCBI B36 
genome assembly (SNP list is provided in Table S2). We did not consider SNPs from any regulatory 
regions outside WWC1 and TLN2 genes. Thus, all the SNPs falling into the boundaries of WWC1 and 
TLN2 genes and typed in all the study cohorts (discovery EADI1 and the 3 replication cohorts: 
GERAD1, RS, and ADGC) were exhaustively tested for 2-way intergenic interactive association with 
AD, in males and females separately. We used logistic regression adjusted for age and genetic 
population stratiﬁcation as before. The number of in-dependent tests (Nyholt, 2004) was 1564 (of 
6664 total). All obtained p-values (not corrected for multiple testing pnominal)forEADI1, GERAD1, 
RS, and ADGC were meta-analyzed using Fisher’scombined p-value (Fisher, 1948) and Stouffer’s 
Zscore(Stouffer et al., 1949) methods, giving rise to meta-analysis p-values (pmeta). Details on the 
applied signiﬁcance criteria are described in the Note 4. 
2.4. Functional analysis and biological validation 
We used transcriptome analysis to assess coexpression of WWC1 and TLN2 in temporal cortex and 
cerebellum human brain regions with data from the brain expression GWA study (eGWAS) (Allen et 
al., 2012; Zou et al., 2012)(Note 5). The laboratory fruit ﬂy Drosophila melanogaster was used to 
further explore the role of WWC1 and TLN2 in model organisms (Note S6). In addition, formalin-ﬁxed 
temporal cortexes of male AD patients were used to perform brain immunohistochemistry (Note 
S7). The latter was performed in 2 independent labs to robustly establish reproducibility. To assess 
subcellular localization of WWC1 and TLN2, we performed immunoﬂuorescence and confocal 
microscopy analyses (Note S8). We also investigated the presence of WWC1 and TLN2 in the same 
complex via IP analysis (Note S9). Molecular mechanisms of interaction be-tween WWC1 and TLN2 
were modeled via protein docking (Note S10) and molecular dynamics in silico experiments (Note 
S11). 
The entire analysis protocol is described in Fig. 1. 
  
  
 
  
 
3. Results 
3.1. Synergy between variants of WWC1 and TLN2 in association to AD 
Both parametric (BOOST) and nonparametric (MB-MDR) analyses highlighted epistasis between the 
SNPs rs3733980 and rs7175766 (minor allele frequencies¼0.365, 0.307 in EADI1, respectively) as 
genome-wide signiﬁcant in males (BOOST: pBonfer-roni-corrected¼0.018, MB-MDR: ppermutation-
based¼0.005). Case/control distributions within the 9 multilocus genotype combinations and MB-
MDR “high risk”/“low risk” labeling are in the Table S3. Only rs3733980 also showed a main effect 
(pnominal¼0.015, trend test), which would not withstand stringent multiple testing correction. The 
identiﬁed epistasis signal remained statistically signiﬁcant in a logistic regression model accounting 
for age and the ﬁrst 4 PCs (pBonferroni-corrected¼0.0165). The APOE gene did not confound the 
identiﬁed interaction because we found no dependence between the APOE ε4 AD-risk allele and the 
9-level categorical SNP pair for these SNPs (p-value¼0.999,c28). No female-speciﬁc epistasis was 
identiﬁed (BOOST, MB-MDR p>0.05). 
3.2. Statistical replication of epistasis between WWC1 and TLN2 
We considered all pairwise intergenic interactions between the directly genotyped 68 SNPs of 
WWC1 and 98 SNPS of TLN2 (Table S2) for follow-up replication analysis in both sexes with the 
GERAD1, RS, and ADGC data sets. In males, the SNP pair rs3733980 and rs7175766 was signiﬁcant in 
a single study (EADI1: pBonferroni-corrected¼5.29*10฀10). Rs7175766 appeared 4 times in the top 
10 male-speciﬁc meta-analysis results but did not show any marginal association with AD 
(pnominal¼0.546, trend test). Interaction be-tween rs1477307 and rs4077746 was found in 3 study 
populations (EADI1: pnominal¼0.040, RS: pnominal¼9.37*10฀4, and ADGC: pnominal¼5.06*10฀5, 
but not in GERAD1: pnominal¼0.544; Fisher’s combined pmeta-Bonferroni-corrected¼2.74*10฀3, 
and Stouffer’s Z score pmeta-Bonferroni-corrected¼9.02*10฀3; Table S4). In females, similar meta-
analysis gave no replicable epistasis signals (Table S5). 
3.3. Functional analysis and biological validation 
Transcriptome analysis revealed signiﬁcant positive association between expression levels of WWC1 
(probe ID - ILMN_1658619) and TLN2 (probe ID - ILMN_1700042) in temporal cortex brain samples 
from autopsied AD subjects (b¼0.17, p¼0.01) and from combined autopsied AD and non-AD subjects 
(b¼0.20, p¼0.0003). These associations were mostly driven by females (temporal cortex from 
autopsied AD females: b¼0.28, p¼0.005, combined autopsied AD and non-AD females b¼0.20, 
p¼0.016) but were not prominent in males. This association was only marginally signiﬁcant for 
autopsied non-AD subjects (b¼0.19, p¼0.05). In the cerebellar tissue, no signiﬁcant associations 
between expression levels of WWC1 and TLN2 genes were observed (Table S6). 
We also tested whether WWC1 and TLN2 could modulate AD physiopathology in human Tau (2N4R)-
expressing Drosophila, an in vivo model of AD (review (Gistelinck et al., 2012)). Kibra, ortholog of 
WWC1 (Fig. 2AeC), and rhea, ortholog of TLN2 (Fig. 2A and D and E), were tested as modiﬁers of Tau 
toxicity in Drosophila eye. In Drosophila, kibra belongs to the growth controlling Hippo pathway. 
Gain (loss) of kibra results in smaller (bigger) eyes (Baumgartner et al., 2010), which we also 
observed (Fig. 2A and B). Expression of human Tau (2N4R) in the eye with the GMR driver resulted in 
smaller rough eyes. The eye size was partially restored in kibra2/þ haploinsufﬁcient background, on 
RNAi-mediated knockdown of kibra (Fig. 2B and C) and in rhea1/þ haploinsufﬁcient background (Fig. 
2D and E). Coexpression of kibra with Tau resulted in lethality and the only escapers that we 
obtained had smaller eyes. For kibra knockdown and kibra overexpression, the effect may be 
additive as in both conditions without Tau expression, ﬂy eyes are respectively bigger and smaller 
(Fig. 2A and B). For kibra haploinsufﬁciencies, only 1 of 4 independent null mutations restored the 
eye size precluding us to ﬁrmly conclude that kibra interacts with Tau in Drosophila eye. The result in 
the rhea1/þ haploinsufﬁcient background (Fig. 2D and E) suggested that rhea interacted functionally 
with human Tau in Drosophila eye. 
Immunohistochemistry of the brain of a male autopsied AD patient indicated strong expression of 
WWC1 in the soma of neuronal cells throughout the temporal lobe of the cerebral cortex (Fig. 3). In 
these neurons, WWC1 presented in the cytoplasm with presumed membrane and/or cytoskeleton 
associations and strong neuritic accumulations in some cells. TLN2 also presented in the cytoplasm 
of neuronal cells, although immunoreactivity was low. In addition to the weak neuronal signal, a 
strong TLN2 signal was detected in the endothelial cells of blood vessels. 
We also performed coimmunoﬂuorescent staining analyses of human Braak I and Braak VI brains 
(Braak and Braak, 1991)(Fig. 4).  After performing quantitative pixel intensity spatial correlation 
analysis (extracting Pearson’s, Manders’, and Costes’ parameters [autothreshold and randomization] 
(Bolte and Cordelieres, 2006)), we determined that TLN2 (Talin2) and WWC1 (aka KIBRA) colocalized 
in all cases. Interestingly, WWC1 staining appeared to be more cellular in Braak I compared to Braak 
VI tissue, where the staining appeared stronger and more widely distributed. 
In complement, we conﬁrmed colocalization of WWC1 and TLN2 in HeLa cell lines and in mouse N2a 
neuroblastoma cells. When overexpressed in HeLa cells, WWC1 displayed diffuse cytoplasm 
localization and small perinuclear rings (Fig. 5, Flag-WWC1), and TLN2-GFP displayed cytoplasmic 
focal adhesion localization with elongated ﬁbrillar adhesions through the cell body (Fig. 5, TLN2-
GFP), consistent with previous studies (Kremerskothen et al., 2003; Praekelt et al., 2012). 
Coexpression of both WWC1 and TLN2 dramatically changed TLN2 localization. In the presence of 
WWC1, 
 
  
 
 
TLN2-GFP appeared concentrated in cytoplasmic foci (Fig. 5, compare GFP staining for TLN2 and 
WWC1þTLN2) surrounded by Flag-WWC1 rings (Fig. 5,WWC1þTLN2-GFP, merge image). In N2a cells, 
WWC1 and TLN2 were found to colocalize in cytoplasm and in ﬁlopodia-like protrusions (Fig. S1). 
However, different colocalization patterns observed in N2a cells may be due to different levels of the 
proteins expressions. 
Furthermore, IP analysis both in human brain samples and in HEK293 cells indicated the presence of 
WWC1 and TLN2 in the same protein complex. The levels of the 2 proteins were variable in all 
conditions and brain regions queried (Braak I and Braak VI brains (Braak and Braak, 1991), Fig. 6A 
[upper panel]). WWC1 coimmunoprecipitated with the anti-TLN2 antibody (Fig. 6A [lower panel]); as 
expected, TLN2 bands were evident in the Western blot. Interestingly, when the WWC1 antibody 
was used, TLN22 bands were absent (Fig. 6A [lower panel]). These data suggest that the anti-WWC1 
antibody could competitively disrupt the TLN2 and WWC1 interaction. In HEK293 cells, TLN2-GFP 
speciﬁcally copuriﬁed with Flag-WWC1 when both proteins were overexpressed together (Fig. 6B). 
To model molecular mechanisms of interaction between WWC1 and TLN2, we performed protein 
docking and molecular dynamics in silico experiments. We determined the top 10 ranked 
WWC1/TLN2 poses (Fig. S2) via ClusPro 2.0 docking server (Comeau et al., 2004a,b; Kozakov et al., 
2006). Poses 2 and 7 showed the most favorable conditions for complex formation as their average 
MM/PBSA protein-ligand binding free energies (dGbind) were amongst the most negative showing 
the lowest dispersion over the course of the 50 ns aqueous simulations. In all 50 ns molecular 
dynamics simulations, WWC1 and TLN2 remained physically associated in a complex throughout the 
entire course of simulation. The average dGbind remained negative for all 10 poses (dGbind ranged 
from -16 to -227 kJ/mol indicating the size of the binding afﬁnity between the 2 proteins; Table S7 
and Fig. S3). 
4. Discussion 
This is the ﬁrst contribution showing (sex-speciﬁc) biological epistasis in AD between genes identiﬁed 
via exhaustive genomic epistasis analysis: WWC1 (WW and C2 domain containing 1 or kidney and 
brain expressed protein, aka KIBRA) and TLN2 (talin 2). WWC1 is expressed in brain regions 
responsible for learning and memory (hippocampus and cortex) and is involved in maintaining of 
synaptic plasticity (Vogt-Eisele et al., 2014). TLN2 expression is restricted to the heart, skeletal 
muscle, and brain (synapses and focal adhesions) (Di Paolo et al., 2002). It plays an important role in 
the assembly of actin ﬁlaments (particularly affecting actin dynamics and clathrinmediated 
endocytosis at neuronal synapses (Morgan et al., 2004)) and in spreading and migration of various 
cell types. WWC1 has already been associated with memory-related disorders including AD (Burgess 
et al., 2011; Corneveaux et al., 2010; Papassotiropoulos et al., 2006; Rodriguez-Rodriguez et al., 
2009), whereas TLN2 has not. However, in our study, rhea (ortholog of TLN2 in Drosophila) 
modulated Tau toxicity in Drosophila and thus may be involved in AD pathology. Interestingly, recent 
studies identiﬁed several other components of the cell adhesion pathway as modiﬁers of Tau toxicity 
in Drosophila (Dourlen et al., 2016; Shulman et al., 2014). Studying the mechanisms of the identiﬁed 
epistatic interaction, we performed comprehensive functional biological experiments. WWC1 and 
TLN2 were coexpressed in the temporal cortex brain tissue (responsible for learning and memory) of 
AD subjects, colocalized in both brain tissue cells, in neuroblastoma N2a and HeLa cell lines, and 
coimmunoprecipitated both in brain tissue and HEK293 cells. The physical interaction between 
WWC1 and TLN2 was also supported by in silico experiments where the binding afﬁnity between the 
2 proteins was pretty strong with favorable conditions for forming a stable protein complex. 
We may speculate on the involvement of WWC1 and TLN2 in common signaling pathways connected 
to signal transduction via synapses that are impaired when dementia symptoms and AD progress. 
Because overexpression of WWC1 was previously associated with AD (Burgess et al., 2011), we 
speculate that impairment expression of WWC1 and/or TLN2 proteins may destabilize actin 
ﬁlaments. Additional work is required to further describe a functional interplay between WWC1 and 
TLN2 and to explain why we observed the interaction at an individual level for both sexes, whereas 
we could detect association with AD only in males at a population level (despite of the theoretical 
power loss for epistasis detection in a sample stratum of males). A few explanations are possible and 
should be investigated in detail: the inﬂuence of sex hormones on the epistasis manifestation, the 
involvement of a third interacting component (i.e., an interacting gene) linked to the sex 
chromosomes, other types of sex-speciﬁc variant(s) in WWC1 and TLN2, among others. Regardless, 
our ﬁndings provide impetus for an in-depth search of AD-related mutation(s) in WWC1 and TLN2 
genes to better explore and grasp biological mechanisms underlying the identiﬁed sex-speciﬁc 
epistasis signals. Targeted next-generation sequencing of the interacting genes may facilitate the 
identiﬁcation of new functional mutations (either common or rare) that play a role in protein 
structure, stability, solubility, folding, and afﬁnity of interaction with ligand(s), to name a few. 
 
 
There is still a big divide between statistical epistasis and biological epistasis. The ambition in 
detecting statistical epistasis is to close this gap by improved analysis protocols and to formulate 
guidelines toward the interpretation of statistical ﬁndings in the context of epistasis. The ﬁeld has 
evolved a lot over the last decade, in this sense. This does not change the fact that indeed, the 
power of a genome-wide epistasis screening (GWAI analysis) using a single study is much smaller 
than the power of a corresponding main effects GWA analysis using the same data (Gauderman, 
2002). Our experience with large-scale epistasis studies is consistent with this, usually only giving 
rise to 1 or 2 reliable statistical ﬁndings (i.e., ﬁndings for which we can rule out numerical instability 
issues or strong main effects overtaking the joint effects of the loci involved). Regardless, results 
dating back from already suggested that bio-logical inference from statistical models is not a utopia 
(Moore, 2005). 
5. Conclusion 
In this research, we aimed to identify novel gene/protein targets to pave the way toward novel 
biochemical pathways related to AD via SNP panels as a starting point. By following a rigorous 
analytic genome-wide epistasis detection protocol (Gusareva and Van Steen, 2014), which minimizes 
false positive ﬁndings and enhances functional relevance, the statistically replicable epistasis was 
identiﬁed. A series of biological experiments indicated novel protein-protein interaction between 
WWC1 and TLN2 that can potentially be a medical target for the cure of AD. To our knowledge, this 
is the ﬁrst report in AD where a hypothesis-free screening led to evidence for replicable statistical 
interaction and where functional studies were performed beyond the transcriptome. 
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